The clinical development of DCprime’s therapeutic candidates currently focuses on treating hematological malignancies, such as acute myeloid leukemia and Myelodysplastic syndrome (MDS). Both diseases have a high risk of relapse, even after initial response to chemotherapy. Repeated treatment or a bone marrow transplant are the only means currently available to control or cure these diseases, so there is a dire need to develop additional therapies. We aim to develop a new class of relapse vaccines to address this need by boosting the patients’ immune system to obtain disease control.

Development Status

DCP-001 is currently being evaluated in a multi-center European Phase II trial in Acute Myeloid Leukemia (AML) patients who have responded to treatment with chemotherapy but are not able to undergo bone marrow transplantation. Patients in complete remission but with measurable residual disease (MRD) will be included. Immune responses to DCP-001 vaccination and effects on MRD will be monitored to evaluate the efficacy of this relapse vaccine.

More details on the ADVANCE II study, as well as participating hospitals under the Horizon2020 AML-VACCiN program, can be found at or on

DCP-001 has previously been evaluated in patients with AML in a Phase I clinical study with top-line data having been published in Cancer Immunology, Immunotherapy in mid-2018 and long-term follow-up and survival data presented at ASH 2019. The primary objectives of the study (feasibility and safety) were achieved, with 10 out of the 12 patients completing the vaccination program. Treatment was well-tolerated and generated both cellular and humoral immune responses.

For more information on the Phase 1 trial, please go to

DCP-001 has been granted Orphan Drug Status in the US and the EU.

Development Outlook

DCprime intends to expand the current development plan for DCP-001 by adding a combination therapy trial with a hypomethylating agent in patients with AML or Myelodysplastic syndrome (MDS).

In addition, DCprime has a number of preclinical programs, including in ovarian cancer and multiple myeloma (Leaf et al., J Immunother. 2017 Nov/Dec;40(9):315-322).

DCprime is also investigating novel vaccination concepts for both solid and blood-borne tumors.